Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Implementing clinical education of medical students in hospital communities: experiences of healthcare professionals.

Alsiö Å, Wennström B, Landström B, Silén C.

Int J Med Educ. 2019 Mar 27;10:54-61. doi: 10.5116/ijme.5c83.cb08.

2.

PCR Detection of Respiratory Pathogens in Asymptomatic and Symptomatic Adults.

Sundell N, Andersson LM, Brittain-Long R, Sundvall PD, Alsiö Å, Lindh M, Gustavsson L, Westin J.

J Clin Microbiol. 2019 Jan 2;57(1). pii: e00716-18. doi: 10.1128/JCM.00716-18. Print 2019 Jan.

3.

Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience.

Waldenström J, Färkkilä M, Rembeck K, Norkrans G, Langeland N, Mørch K, Pedersen C, Rauning Buhl M, Nieminen U, Nuutinen H, Alsiö Å, Holmström L, Jungnelius R, Lund K, Rubensson A, Torell E, Westin J, Lagging M.

Scand J Gastroenterol. 2016 Mar;51(3):337-43. doi: 10.3109/00365521.2015.1087588. Epub 2015 Sep 29.

4.

Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3.

Alsiö Å, Rembeck K, Askarieh G, Christensen PB, Färkkilä M, Langeland N, Buhl MR, Pedersen C, Mørch K, Haagmans BL, Nasic S, Westin J, Hellstrand K, Norkrans G, Lagging M.

PLoS One. 2012;7(5):e37521. doi: 10.1371/journal.pone.0037521. Epub 2012 May 24.

5.

Impact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3.

Rembeck K, Alsiö A, Christensen PB, Färkkilä M, Langeland N, Buhl MR, Pedersen C, Mørch K, Westin J, Lindh M, Hellstrand K, Norkrans G, Lagging M.

PLoS One. 2012;7(1):e29370. doi: 10.1371/journal.pone.0029370. Epub 2012 Jan 13.

6.

Early quantification of HCV core antigen may help to determine the duration of therapy for chronic genotype 2 or 3 HCV infection.

Alsiö A, Jannesson A, Langeland N, Pedersen C, Färkkilä M, Buhl MR, Mørch K, Westin J, Hellstrand K, Norkrans G, Lagging M; NORDynamIC Study Group.

Eur J Clin Microbiol Infect Dis. 2012 Jul;31(7):1631-5. doi: 10.1007/s10096-011-1486-5. Epub 2011 Nov 24.

PMID:
22113307
7.

Look-back screening for the identification of transfusion-induced hepatitis C virus infection in Sweden.

Ydreborg M, Söderström A, Håkanson A, Alsiö A, Arnholm B, Malmström P, Hellstrand K, Westin J, Lagging M.

Scand J Infect Dis. 2011 Jul;43(6-7):522-7. doi: 10.3109/00365548.2011.562526. Epub 2011 Mar 7.

PMID:
21375426
8.

Early determination of hepatitis C virus RNA may help to decide the duration of therapy for chronic hepatitis C virus genotype 2/3 infection.

Lagging M, Alsiö A, Langeland N, Pedersen C, Färkkilä M, Buhl MR, Mørch K, Hellstrand K, Norkrans G.

Hepatology. 2011 Mar;53(3):1067-8. doi: 10.1002/hep.23962. Epub 2010 Dec 28. No abstract available.

PMID:
21374685
9.

Ribavirin plasma concentration is a predictor of sustained virological response in patients treated for chronic hepatitis C virus genotype 2/3 infection.

Pedersen C, Alsiö Å, Lagging M, Langeland N, Färkkilä M, Buhl MR, Mørch K, Westin J, Sangfelt P, Norkrans G, Christensen PB; NORDynamicIC Study Group.

J Viral Hepat. 2011 Apr;18(4):245-51. doi: 10.1111/j.1365-2893.2010.01303.x.

PMID:
20384961
10.

Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C.

Askarieh G, Alsiö A, Pugnale P, Negro F, Ferrari C, Neumann AU, Pawlotsky JM, Schalm SW, Zeuzem S, Norkrans G, Westin J, Söderholm J, Hellstrand K, Lagging M; DITTO-HCV and NORDynamIC Study Groups.

Hepatology. 2010 May;51(5):1523-30. doi: 10.1002/hep.23509.

PMID:
20186843
11.

Nonresponder patients with hepatitis C virus genotype 2/3 infection: a question of low systemic interferon concentrations?

Alsiö A, Christensen PB, Färkkilä M, Langeland N, Buhl MR, Pedersen C, Mørch K, Haagmans BL, Westin J, Hellstrand K, Norkrans G, Lagging M.

Clin Infect Dis. 2010 Feb 15;50(4):e22-5. doi: 10.1086/650006.

PMID:
20088695
12.

A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection.

Westin J, Ydreborg M, Islam S, Alsiö A, Dhillon AP, Pawlotsky JM, Zeuzem S, Schalm SW, Ferrari C, Neumann AU, Hellstrand K, Lagging M; DITTO-HCV Study Group.

Scand J Gastroenterol. 2008 Jan;43(1):73-80.

PMID:
18938750
13.

Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection.

Lagging M, Langeland N, Pedersen C, Färkkilä M, Buhl MR, Mørch K, Dhillon AP, Alsiö A, Hellstrand K, Westin J, Christensen P, Leutscher P, Norkrans G; NORDynamIC Study Group.

Hepatology. 2008 Aug;48(2):695. doi: 10.1002/hep.22450. No abstract available.

PMID:
18666232
14.

Cerebrovascular complications in patients with left-sided infective endocarditis are common: a prospective study using magnetic resonance imaging and neurochemical brain damage markers.

Snygg-Martin U, Gustafsson L, Rosengren L, Alsiö A, Ackerholm P, Andersson R, Olaison L.

Clin Infect Dis. 2008 Jul 1;47(1):23-30. doi: 10.1086/588663.

PMID:
18491965
15.

Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection.

Lagging M, Langeland N, Pedersen C, Färkkilä M, Buhl MR, Mørch K, Dhillon AP, Alsiö A, Hellstrand K, Westin J, Norkrans G; NORDynamIC Study Group.

Hepatology. 2008 Jun;47(6):1837-45. doi: 10.1002/hep.22253.

PMID:
18454508
16.

Impact of disease severity on outcome of antiviral therapy in treatment-naïve patients with chronic hepatitis C.

Westin J, Hellstrand K, Alsiö A, Ydreborg M, Ferrari C, Neumann AU, Pawlotsky JM, Schalm SW, Zeuzem S, Verhey-Hart E, Lagging M.

Hepatology. 2007 May;45(5):1333-4; author reply 1334. No abstract available.

PMID:
17464982

Supplemental Content

Support Center